Generic drug makers not being held accountable
Carmen Scott

In this light of the financial climate, savvy consumers must do a lot to ensure optimum bang for their buck—clip coupons, buy items when they go on sale and use the generic option when filling prescriptions. All these shopping traits are great for saving money in the short term. After all, every little bit helps. Or does it?

Last year, the U.S. Supreme Court ruled that a generic drug manufacturer cannot be held liable if a consumer has a negative reaction to its generic medication. This means that the medicine a patient takes must be purchased as a name brand in order for that patient’s rights to be protected. In other words, if a patient fills a generic prescription, thinking that doing so will save money, that patient gives up the right to file a suit and the right to a trial by jury if he/she experiences a serious negative reaction.

As shocking as this ruling is, the reality is that some insurance companies will not cover the cost of name brand drugs if a generic version is available. The out-of-pocket expenses for name brand drugs can be so costly that financially strapped people may choose not to take the medication or may ration out the medication rather than take it at the prescribed dosage.  Gambling with one’s health is not a choice anyone should have to make.

In April 2012, The Patient Safety and Generic Labeling Improvement Act was introduced in the Senate by Senator Patrick Leahy, with companion legislation introduced in the House of Representatives, which would address this problem. If this act passes in Congress, generic and name brand drug manufactures will be held to the same labeling standards. The Supreme Court’s original ruling was generally based on the idea that generic drug manufacturers could not control their warning label and could, therefore, not be held liable if a patient had a negative reaction. The Patient Safety and Generic Labeling Improvement Act attempts to correct this problem by permitting generic drug manufacturers the ability to change and update labels, especially as they learn of new side effects or risks. By allowing generic drug manufacturers to modify their products’ labels, the rights that currently only name brand drug users enjoy should also protect generic drug consumers.

Do you support The Patient Safety and Generic Labeling Improvement Act? Contact your Senator and ask them to push for its passing.

Carmen Scott

About Carmen Scott

Carmen Scott helps lead Motley Rice’s Medical practice group, managing complex personal injury and economic recovery damages cases on behalf of victims of medical negligence, harmful prescription drugs or misconduct. Carmen represents victims of potentially harmful pharmaceutical drugs and devices, focusing on litigation involving women’s products. She has been on the forefront of complex, national contraceptive litigation involving products such as Nuvaring®, Yasmin® and Yaz®. Carmen currently represents clients in cases involving claims of atypical, spontaneous femur fractures occurring with long-term Fosamax® therapy, as well as in cases filed by women who have suffered debilitating or even life-threatening health problems allegedly caused by the Mirena® IUD contraceptive. Active in her community, she serves as Vice Chair of the Board for the Make-A-Wish Foundation of South Carolina, fundraising and promoting the Foundation's mission, as well as serving as a "wish-granter." View Carmen's full bio.

Leave a Reply

Your email address will not be published. Required fields are marked *

HTML tags are not allowed.